Amgen news and information

Amgen's blockbuster $10.4 billion bid to acquire Onyx Pharmaceuticals topped Modern Healthcare's list of largest mergers and acquisitions last month. However, total deals in August fell to 70, down from 99 in July. Acquisitions in the drugs and biologics sector continued to dominate merger activity...
FULL STORY »

Biotech drugmaker Amgen is reportedly close to buying cancer drugmaker Onyx Pharmaceuticals for about $10.5 billion.
FULL STORY »

At least 10 physicians received more than $20,000 in payments and other transfers of value from biotechnology giant Amgen in the first quarter of this year, according to newly public data published by the company.
FULL STORY »

Dr. Nogah Haramati, a radiologist based in New York, recently cancelled a meeting with a vendor—one of the many equipment manufacturers and software developers who routinely offer free dinners and lectures to ply their wares.
FULL STORY »

The CMS and Medicare beneficiaries could have saved an estimated $510 million on drugs used to treat end-stage renal disease in 2011 if the reimbursement rate more accurately reflected current usage of these drugs, according to a report from HHS' inspector general's office.
FULL STORY »

Some of the nation's largest for-profit hospital chains are sitting on mounting cash piles, suggesting to analysts that a wave of dealmaking may be in the offing.
FULL STORY »

Legislators in Washington all claim they want to hold down healthcare spending, recognizing it is the main driver of the nation's long-term deficit.
FULL STORY »

Less than one month after the Government Accountability Office called on the CMS to recalculate payments to dialysis providers, the fiscal cliff compromise sets in motion cuts that would squeeze out $4.9 billion in savings.
FULL STORY »

Victory Pharma has entered into an $11.4 million settlement to resolve allegations that it used pricey trips, tickets and dinners to entice physicians to prescribe its products.
FULL STORY »

A federal judge accepted biotechnology giant Amgen's guilty plea that it illegally marketed its anemia drug Aranesp, clearing the way for a $762 million settlement agreement.
FULL STORY »